Blueprint Medicines stockholders elect three Class I directors, approve say-on-pay and auditor at 2025 meeting

Blueprint Medicines Corp

Elected Jeffrey W. Albers, Mark Goldberg, M.D., and John Tsai, M.D. as Class I directors for three-year terms expiring in 2028.
Non-binding say-on-pay vote passed with 57,714,069 votes for, 2,450,825 against, and 25,744 abstaining; 2,342,656 broker non-votes.
Ratification of Ernst & Young LLP as independent auditor for FY2025 approved with 62,209,853 votes for, 288,580 against, 34,861 abstaining.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.